Investigators assessed country, regional, and global incidence of serologically confirmed HIV, anti-hepatitis C virus, and hepatitis B virus prevalence according to gender in people who inject drugs.
As part of the World Health Organization’s goal to eliminate viral hepatitis as a global health threat by 2030, the incidence of chronic new infections must decrease by 90%.
The most pressing issues with respect to racial disparities reside in the medical system, rather than the patient.
Modern treatments for hepatitis C have improved outcomes and experiences for patients.
The statement encourages hepatitis B virus screening in high-risk populations, vaccination of all unvaccinated at-risk adults, and linkage to care for hepatitis B-positive patients.
State-level hepatitis C virus testing laws can increase the number of individuals who know their HCV status and help those infected with HCV get access to care.
About 1000 new cases of perinatal hepatitis B infection are identified annually in the United States, says AAP.
Mavyret has been approved by the FDA to treat adults with certain types of chronic hepatitis C virus.
Sofosbuvir, velpatasvir and voxilaprevir are used for patients who have failed with direct-acting antivirals.
Many infections stemmed from rising use of injected drugs linked to the current opioid epidemic, officials say.
